LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High – Time to Buy?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) reached a new 52-week high on Thursday . The stock traded as high as $106.99 and last traded at $105.88, with a volume of 116408 shares. The stock had previously closed at $103.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LMAT shares. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Finally, Oppenheimer reiterated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

The firm has a 50 day moving average price of $93.48 and a two-hundred day moving average price of $86.61. The company has a market capitalization of $2.43 billion, a P/E ratio of 59.00, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.59%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of LeMaitre Vascular by 4.5% during the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock worth $50,403,000 after purchasing an additional 23,443 shares in the last quarter. M&T Bank Corp bought a new position in LeMaitre Vascular in the 3rd quarter worth approximately $1,551,000. Barclays PLC raised its position in LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the last quarter. MML Investors Services LLC lifted its holdings in LeMaitre Vascular by 2.8% during the 3rd quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock worth $660,000 after buying an additional 191 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in LeMaitre Vascular in the 3rd quarter valued at $344,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.